| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/08/2002 | WO2001021799A9 Traf4 associated cell cycle proteins, compositions and methods of use |
| 08/08/2002 | WO2001010406A3 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow |
| 08/08/2002 | WO2001009328A9 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof |
| 08/08/2002 | WO2001009325A9 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 08/08/2002 | WO2001009090A3 Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 08/08/2002 | US20020108131 Screening drugs for use in treatment of heart defects and stroke; obtain animal, incubate with drug, monitor animal for adjustment in phenotype |
| 08/08/2002 | US20020107420 For use as excipient in pharmaceuticals and food processing; compressibility |
| 08/08/2002 | US20020107414 Method of prostaglandin synthesis |
| 08/08/2002 | US20020107406 Calcium receptor-active compounds |
| 08/08/2002 | US20020107402 Aminoaryl oxazolidinone N-oxides |
| 08/08/2002 | US20020107400 Cyanoguanidines as cell proliferation inhibitors |
| 08/08/2002 | US20020107396 3-cycloalkyl- or propyl-2-(3,4-dihalophenyl)-N-quinolinyl-, quinazolinyl-, or quinoxolinyl-propionamide. |
| 08/08/2002 | US20020107393 The crystalline monohydrate form provides increased stability over the anhydrous form. |
| 08/08/2002 | US20020107392 Quinolinone derivatives |
| 08/08/2002 | US20020107385 Human breast tumor-specific proteins |
| 08/08/2002 | US20020107368 Helicobacter proteins, gene sequences and uses thereof |
| 08/08/2002 | US20020107364 Compositions and methods for regulating bacterial pathogenesis |
| 08/08/2002 | US20020107363 B7-Like molecules and uses thereof |
| 08/08/2002 | US20020107359 Protein model for use in drug design in human therapeutics |
| 08/08/2002 | US20020107330 Drug delivery compositions and medical devices containing block copolymer |
| 08/08/2002 | US20020107292 Primary composition comprising a lipophilic bioactive compound |
| 08/08/2002 | US20020107291 Clear, injectable formulation of an anesthetic compound |
| 08/08/2002 | US20020107289 Regulation of phospholipase D activity |
| 08/08/2002 | US20020107286 Microbicides |
| 08/08/2002 | US20020107285 Novel compounds to treat diabetes and associated conditions |
| 08/08/2002 | US20020107283 Halogenated 2-phenyl-1,2-ethanediol monocarbamate enantiomer |
| 08/08/2002 | US20020107280 Selective COX II inhibitor |
| 08/08/2002 | US20020107279 Prevents oxidative tissue damage to organs, particularly the central nervous system including the brain in mammals afflicted with disease-induced ischemic trauma, particularly stroke. |
| 08/08/2002 | US20020107278 Substituted azepino[4,5b]indole derivatives |
| 08/08/2002 | US20020107276 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist |
| 08/08/2002 | US20020107275 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation |
| 08/08/2002 | US20020107273 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 08/08/2002 | US20020107272 Anti-HIV imidazolone derivatives |
| 08/08/2002 | US20020107271 Heterocyclic aromatic oxazole compounds and use thereof |
| 08/08/2002 | US20020107270 Selective inhibitory action on cyclooxygenase- 2 and are expected to be useful as anti-inflammatory agents with less side-effects such as digestive tract disorders. |
| 08/08/2002 | US20020107267 Controlling attention and memory by altering neuronal carbonic anhydrase activity |
| 08/08/2002 | US20020107265 Emulsion comprising: (a) an aqueous phase; (b) an oil phase comprising a structured triglyceride; and (c) an emulsifier. |
| 08/08/2002 | US20020107264 Optionally oxygenated hydrogenated thiophenes, thiopyrans and thiomorpholines containing hydroxyethylamine groups |
| 08/08/2002 | US20020107263 Squaric acid derivatives |
| 08/08/2002 | US20020107262 Substituted imidazopyridines |
| 08/08/2002 | US20020107261 Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
| 08/08/2002 | US20020107260 Method for treating cancer with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof |
| 08/08/2002 | US20020107259 Analgesic combination of oxycodone and SC-58215 |
| 08/08/2002 | US20020107257 Treatments for restless legs syndrome |
| 08/08/2002 | US20020107255 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). |
| 08/08/2002 | US20020107254 P-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-N-pyridin-2-yl-benzamide, |
| 08/08/2002 | US20020107253 Novel 4,5,-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof |
| 08/08/2002 | US20020107252 Novel Compounds |
| 08/08/2002 | US20020107251 4-(hetero)aryl-3-oxo-3,4-dihydropyrido(2,3-b)pyrazine derivatives; prophylactic or therapeutic treatment of phosphodiesterase IV and tumor necrosis factor mediated diseases |
| 08/08/2002 | US20020107250 Orally deliverable cyclooxygenase-2 inhibitor of low water solubility, for example celecoxib, and a glycol ether, for example diethylene glycol monoethyl ether. |
| 08/08/2002 | US20020107249 Administering a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine of at least about 5000, such as reboxetine; treating and prophylaxis of various psychological and neurological disorders |
| 08/08/2002 | US20020107248 Treatment of precancerous lesions; especially for those with lesions of the breast or with colonic polyps |
| 08/08/2002 | US20020107247 Method of treating sexual disturbances |
| 08/08/2002 | US20020107245 Method for treating fibrotic diseases or other indications IVC |
| 08/08/2002 | US20020107244 Combination treatment for depression |
| 08/08/2002 | US20020107243 Nitro-benzamides useful as Anti-arrhythmic agents |
| 08/08/2002 | US20020107242 Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| 08/08/2002 | US20020107241 N-heterocyclic derivatives useful for treating or preventing neuronal damage associated with neurological disease |
| 08/08/2002 | US20020107240 N-substituted glycine derivatives useful for treating or preventing neuronal damage associated with neurological disease |
| 08/08/2002 | US20020107239 Cyclized amide derivatives |
| 08/08/2002 | US20020107238 Topical antibiotic composition for treatment of eye infection |
| 08/08/2002 | US20020107237 Topoisomerase inhibitors |
| 08/08/2002 | US20020107236 Methods of treating sexual dysfunction associated with hypertension |
| 08/08/2002 | US20020107235 Carbamate and hydroxy groups containing phenanthrene derivatives; useful to treat obesity, diabetes and inflammation |
| 08/08/2002 | US20020107234 Lipoic acid derivatives and their use in treatment of disease |
| 08/08/2002 | US20020107233 Useful for treating hypocholesterolemia |
| 08/08/2002 | US20020107232 Methods for producing sterol ester-rich compositions |
| 08/08/2002 | US20020107231 Administering to a patient suffering form autoimmune sialadenitis or Sjogren's disease (autoimmune diseases) toremifene or a salt |
| 08/08/2002 | US20020107230 Methods and formulations for the treatment of female sexual dysfunction |
| 08/08/2002 | US20020107229 Multistage preparation for contraception: 2-4 first stage daily dosage including a natural estrogen, form 16-22 second stage daily dosage portions including a natural or synthetic gestogen and a natural estrogen, and a specific third dosage |
| 08/08/2002 | US20020107225 Use of nucleoside analogues (cytosine or 5-fluorocytosine containing compound) useful for acute or chronic myelogenous leukemia |
| 08/08/2002 | US20020107222 Modified polysaccharides for treatment of cancer |
| 08/08/2002 | US20020107221 Nucleosides with anti-hepatitis B virus activity |
| 08/08/2002 | US20020107220 By replication of the nucleic acids of the viruses in that distribution by use of a defective replication system; virus population lose pathogenic properties, infectiousness; treating viral diseases |
| 08/08/2002 | US20020107218 Using inhibitors such as antisense nucleic acids |
| 08/08/2002 | US20020107214 Using chimeric restriction endonucleases; treating or prophylaxis of a genetic disease |
| 08/08/2002 | US20020107212 Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
| 08/08/2002 | US20020107208 Gabapentin prodrugs and formulations |
| 08/08/2002 | US20020107206 Treatment of acute coronary syndrome with GLP-1 |
| 08/08/2002 | US20020107205 Exposing to a matrix of type I collagen and bone morphogenic protein-4 (BMP-4) |
| 08/08/2002 | US20020107203 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 08/08/2002 | US20020107194 Able to bind to a Notch protein forming Delta-Notch complex |
| 08/08/2002 | US20020107193 Therapeutic uses for IP3 receptor-mediated calcium channel modulators |
| 08/08/2002 | US20020107191 Combination drug therapy |
| 08/08/2002 | US20020107181 Novel hepatitis C virus ("HCV") protease inhibitors and pharmaceutical compositions comprising them optionally with viricide ribavirin and interferon |
| 08/08/2002 | US20020107176 Membrane miscible, amide compound containing a sulfhydril group for exerting antioxidation properties which accumulates within the cytoplasm of cells |
| 08/08/2002 | US20020107173 Method of treating amyloid beta precursor disorders |
| 08/08/2002 | US20020106790 Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells |
| 08/08/2002 | US20020106780 Extracellular matrix polynucleotides, polypeptides, and antibodies |
| 08/08/2002 | US20020106778 Human PTTG polypeptide and method for producing it |
| 08/08/2002 | US20020106776 pth |
| 08/08/2002 | US20020106762 Generating preerential compound for use as prophylactic agent; obtain chemical intermediate, incubate with enzyme, recover prophylactic agent |
| 08/08/2002 | US20020106726 Peptide for use in the treatment of inflammation defects |
| 08/08/2002 | US20020106713 Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule |
| 08/08/2002 | US20020106645 Detecting preferential psychological disorders; obtain tissue sample, detect sequences polymorphism, presence of polymorphism indicates psychological disorders |
| 08/08/2002 | US20020106633 Vitro assay for testing gabapentinoid activity |
| 08/08/2002 | US20020106631 Recombinant, active caspases and uses thereof |
| 08/08/2002 | US20020106415 Interleukin-4production inhibitors |
| 08/08/2002 | US20020106407 Non-invasively delivering an analgesic into a patient's systemic circulation at an initial absorption rate, initial absorption rate; increasing absorption for therapy; providing analgesic to the patient's systemic circulation |
| 08/08/2002 | US20020106405 Pharmaceutical composition for piperidinoalkanol compounds |